These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36672567)

  • 21. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
    Zhou Q; Su J; Zhou T; Tian J; Chen X; Zhu J
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):163-168. PubMed ID: 27936522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. To Treat or Not to Treat? Effect of Urate-Lowering Therapy on Renal Function, Blood Pressure and Safety in Patients with Asymptomatic Hyperuricemia: A Systematic Review and Network Meta-Analysis.
    Tien YY; Shih MC; Tien CP; Huang HK; Tu YK
    J Am Board Fam Med; 2022; 35(1):140-151. PubMed ID: 35039419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
    Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
    BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK; Singh JA
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
    Saag KG; Becker MA; White WB; Whelton A; Borer JS; Gorelick PB; Hunt B; Castillo M; Gunawardhana L;
    Arthritis Rheumatol; 2022 Sep; 74(9):1593-1601. PubMed ID: 35536764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
    Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
    J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
    [No Abstract]   [Full Text] [Related]  

  • 27. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular Safety of Urate Lowering Therapies.
    Kang EH; Kim SC
    Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. African American patients with gout: efficacy and safety of febuxostat vs allopurinol.
    Wells AF; MacDonald PA; Chefo S; Jackson RL
    BMC Musculoskelet Disord; 2012 Feb; 13():15. PubMed ID: 22316106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
    Beslon V; Moreau P; Maruani A; Maisonneuve H; Giraudeau B; Fournier JP
    J Gen Intern Med; 2018 Mar; 33(3):358-366. PubMed ID: 29204974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
    Borghi C; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):983-92. PubMed ID: 27010159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
    Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study.
    Kielstein JT; Heisterkamp M; Jing J; Nadal J; Schmid M; Kronenberg F; Busch M; Sommerer C; Lorenzen JM; Eckardt KU; Köttgen A;
    Clin Kidney J; 2021 Jan; 14(1):277-283. PubMed ID: 33564429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial.
    Timilsina S; Brittan K; O'Dell JR; Brophy M; Davis-Karim A; Henrie AM; Neogi T; Newcomb J; Palevsky PM; Pillinger MH; Pittman D; Taylor TH; Wu H; Mikuls TR
    Contemp Clin Trials; 2018 May; 68():102-108. PubMed ID: 29597007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
    Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC
    Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
    Mackenzie IS; Ford I; Nuki G; Hallas J; Hawkey CJ; Webster J; Ralston SH; Walters M; Robertson M; De Caterina R; Findlay E; Perez-Ruiz F; McMurray JJV; MacDonald TM;
    Lancet; 2020 Nov; 396(10264):1745-1757. PubMed ID: 33181081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.